Protega Pharmaceuticals joins forces in an exclusive agreement with OPOS Solutions software technology platform to improve patient education and chronic pain care

Pharmaceutical and Health Tech companies join efforts to provide pain care prescribers with regulatory compliance-based risk mitigation tools to improve patient care

Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

Protega

March 3, 2025

ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond ™ , is designed to provide multiple levels of protection P...

Protega Pharmaceuticals Receives FDA Approval for ROXYBOND™ (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain

Protega

October 29, 2024

Patented SentryBond™ technology, a first-of-its-kind abuse-deterrent technology, is designed to provide multiple levels of protection and has the pote...

Protega Pharmaceuticals joins forces in an exclusive agreement with OPOS Solutions software technology platform to improve patient education and chronic pain care

The Bradford Era

Download Now

Sign Up for Our Newsletters

Protega Pharmaceuticals joins forces in an exclusive agreement with OPOS Solutions software technology platform to improve patient education and chronic pain care

The Bradford Era

Download Now

Sign Up for Our Newsletters

Help Our Community